ESMO 2024 Prostate Cancer

REVIEW UroToday

Viewing 1-20 of 37 articles

ASTRO 2024: Hyaluronic Acid Rectal Spacer in Locally Recurrent Prostate Cancer with Prior Radiation Receiving SBRT: Feasibility, Safety, and Toxicity

ASTRO 2024: Prostate CAncer integrated Risk Evaluation (P-CARE): A Model to Stratify Risk of Any, Metastatic, and Fatal Prostate Cancer

ASTRO 2024: The Interplay between Acute and Late Toxicity among Patients Receiving Prostate Radiotherapy: A Pooled Analysis of 7 Randomized Trials

ASTRO 2024: Examination of Decipher® Prostate Genomic Classifier in Patients with De Novo Metastatic Disease from a Large Scale Real-World Clinical and Transcriptomic Data Linkage

ASTRO 2024: A Validation Study on the Impact of Decipher® Testing on Treatment Recommendations in African American and Non-African American Men with Prostate Cancer (VANDAAM STUDY)

ASTRO 2024: A Digital Pathology MMAI Algorithm is Associated with Pro-Metastatic Genomic Pathways in Oligometastatic Prostate Cancer

ASTRO 2024: Validation of a Digital Pathology-Based MMAI Model in Oligometastatic Castration-Sensitive Prostate Cancer, including Patients from the STOMP and ORIOLE Phase II Randomized Trial

ASTRO 2024: Rectal Wall Infiltration with Hyaluronic Acid Based Rectal Spacer Reversal Protocol

ASTRO 2024: Impact of Hyaluronic Acid Rectal Spacer Quality Score and Fischer-Valuck Spacer Symmetry Score on Rectal Dosimetry and Acute and Late Gastrointestinal Toxicity Outcomes – An Australian Experience

ASTRO 2024: SBRT versus Conventional Fractionation EBRT Boost for Unfavorable Intermediate and High-Risk Prostate Cancer. Early Results of PBS phase II randomized trial

ASTRO 2024: Focal MR-Guided HDR Brachytherapy Boost Combined with SBRT for Localized Prostate Cancer

ASTRO 2024: F-SHARP: Initial Results of a Multi-Institutional Phase 1/2 Trial of Focal Dose-Escalated Salvage HDR Brachytherapy for Radiorecurrent Prostate Cancer

ASTRO 2024: EMPIRE-2: Volumetric Changes and Acute Toxicity with 68Ga PSMA versus 18F-Fluciclovine PET/CT Guided Post-Prostatectomy Radiation: Final Analysis of a Randomized Trial

ASTRO 2024: MRI-Guided versus CT-Guided SBRT for Prostate Cancer: 2-Year Outcomes from the MIRAGE Randomized Clinical Trial

ASTRO 2024: Dose Escalated Pelvic Lymph Node IMRT with a Simultaneous Hypofractionated Boost to the Prostate for NCCN Very-High Risk Adenocarcinoma of the Prostate, a Prospective Trial

ASTRO 2024: The RAVENS Phase 2 Randomized Trial: Outcomes of RAdium-223 and SABR Versus SABR for oligomEtastatic Prostate caNcerS

ASTRO 2024: Radiation Therapy for Small Cell Neuroendocrine Tumors of the Genitourinary Tract

ASTRO 2024: Combination of Nivolumab Immunotherapy with Radiation Therapy and Androgen Deprivation Therapy in the Management of Gleason Group 5 Prostate Cancer: Final Analysis of a Phase 2 Trial

ASTRO 2024: Hypofractionated, Dose-Escalated Radiation vs. Conventionally Fractionated Radiation for Localized Prostate Cancer: Long-Term Update of a Phase 3, Prospective, Randomized Controlled Trial

ASTRO 2024: Natural History after Likely Cure versus Recurrence after ProsTate RadiOtheRapy (RAPTOR): A Pooled Analysis of More than 13000 Patients from 21 Randomized Controlled Trials

1
2